RJA
NVS icon

Raymond James & Associates’s Novartis NVS Stock Holding History

Raymond James & Associates’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,200
Closed -$1.31M – 3893
2023
Q2 		$1.31M Hold
14,200
– – ﹤0.01% 2328
2023
Q1 		$1.31M Sell
14,200
-14,800
-51% -$1.29M ﹤0.01% 2283
2022
Q4 		$106K Buy
+29,000
New +$2.44M ﹤0.01% 3633

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Raymond James & Associates's NVS Position: Q3 2024 in Review

Raymond James & Associates reduced its Novartis (NVS) stake by 3.4% in Q3 2024, selling an estimated $2.09M and leaving 518,181 shares worth $59.6M. The position accounts for 0.04% of the portfolio, ranked #396.

Raymond James & Associates first reported a position in NVS in Q2 2013 and has held it in 46 quarters since. The position peaked at $150M in Q1 2019. 1,311 funds tracked by Wall St. Rank hold NVS as of Q3 2024.

  • Raymond James & Associates held 518,181 shares of Novartis worth $59.6M as of Q3 2024.
  • Raymond James & Associates sold 18,426 Novartis shares in Q3 2024, an estimated $2.09M.
  • Novartis made up 0.04% of Raymond James & Associates's portfolio in Q3 2024, its #396 holding.
  • Raymond James & Associates first reported a position in Novartis in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Novartis position peaked at $150M in Q1 2019.
  • 1,311 funds tracked by Wall St. Rank held Novartis as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.